Navigation Links
Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
Date:11/8/2008

- Results demonstrate clinically significant reduction in allergic asthma attacks and further define Xolair safety profile in children age six through 11 - this includes 11-year-old children, up to their 12th birthday

- Xolair is the only approved therapy to block IgE, which is associated with approximately 78% of childhood asthma

- Allergic asthma affects 2.5 million children in the US under the age of 18

- Xolair is currently approved for adults and adolescents aged 12 and above; US submission to treat children aged six through 11 planned

SEATTLE, Nov. 8, 2008 /PRNewswire/ -- Data presented today at the American College of Allergy, Asthma & Immunology (ACAAI) show that Xolair(R) (Omalizumab) for Subcutaneous Use significantly reduced asthma attacks in children aged six through 11 with moderate or severe persistent allergic asthma inadequately controlled with inhaled corticosteroids. The study further defines the safety profile of Xolair in this patient population.

The Phase III study showed that children treated with Xolair demonstrated a 31% reduction in clinically significant asthma exacerbations compared to children treated with placebo at 24 weeks. After a year of treatment, children treated with Xolair suffered 43% fewer clinically significant asthma exacerbations than those receiving placebo.

Xolair is a biologic treatment currently approved for people 12 years of age and above with moderate-to-severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. It is the only approved therapy which blocks IgE (immunoglobulin E), a major component of allergic asthma. Genentech, co-marketer of Xolair, plans to submit these data to the US Food and Drug Administration (FDA) seeking to expand the current labeled indication for Xolair.

"Asthma is a life-threatening disease that can have serious h
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
2. Healthy Bones Program Reduces Hip Fractures by 37 Percent, Kaiser Permanente Study Finds
3. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
4. NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
5. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
6. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
7. Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
8. Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients
9. New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
10. New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life
11. Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PRINCETON, N.J. , Dec. 24, 2014 /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today that on ... registered public offering. The Company raised ... offering and intends to use the net proceeds ...
(Date:12/24/2014)... , Dec. 24, 2014  Diplomat Pharmacy, Inc. (NYSE: ... pharmacy, is proud to announce Jennifer Hagerman , ... Diplomat, will take office as the president of the ... induction ceremony will take place Feb. 28, 2015, at ... held at the Renaissance Center in Detroit, ...
(Date:12/24/2014)... 23, 2014 PuraMed BioScience®, Inc., (OTC Pink: ... medicinal and healthcare products, announced it received the initial ... hemp-based, advanced headache relief product, for planned distribution to ... Colorado , Washington State , ... the MigraPure H Advanced headache relief gel formulation completed, ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... Survey Underscores Impact of Disease on Work Status ... today at Digestive Disease Week(R) 2007 (DDW), from,long-term ... 1,& 2) show that subjects with moderately to ... REMICADE(R),(infliximab) in the blinded phase of the trials ...
... 2007 - Synta,Pharmaceuticals Corp., (NASDAQ: SNTA) a ... small,molecule drugs to treat severe medical conditions, ... the Phase 2b clinical,trial in metastatic melanoma ... will be presented at the annual meeting ...
Cached Medicine Technology:Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 2Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 3Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 4Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 5Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 6Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 7Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 8Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 9Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting 2Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting 3
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... various districts of Punjab have been transferred by the ... fuming.// ,The transfer of these doctors in all ... imposed a ban on general transfers in all departments ... Medical Services (PCMS) Association has flayed the large-scale transfer ...
... in India annually and the country stands to lose $236 ... productive working days and// treatment costs, say experts. ... patients and more than two million patients are succumbing to ... IANS. ,Trehan spoke on the eve of World ...
... recent study has shown that several Americans, to the ... asleep, and around 4.5 percent of them use some ... problems.,Dr. Nancy J. Pearson and colleagues from the National ... report in the Archives of Internal Medicine, "Most respondents ...
... The Office for the Co-ordination of Humanitarian Affairs (OCHA) ... Niger following intense flooding from heavy rains// since July. ... five regions, posing serious health risks to them. Over ... reported over the past three weeks across the region. ...
... developed by an international team of cancer immunologists ... Cancer// Research Cancer Vaccine Collaborative (CVC) successfully induced ... late-stage metastatic disease, with results indicating that the ... in some patients, according to a paper to ...
... white blood cell chemistry known to damage kidneys used ... to a federally// funded study in genetically engineered mice ... that when blood flow is cut off and then ... cells called T lymphocytes produce toxic natural chemicals that ...
Cached Medicine News:Health News:India may Lose Over $230 bn from Heart Diseases 2Health News:Sleeping Problems Often Overcome with Alternative medicine 2Health News:A Promising New Vaccination Strategy for Late-Stage Melanoma 2Health News:A Promising New Vaccination Strategy for Late-Stage Melanoma 3Health News:A Promising New Vaccination Strategy for Late-Stage Melanoma 4Health News:White Blood Cells Can Both Hurt and Help Transplanted Kidneys 2Health News:White Blood Cells Can Both Hurt and Help Transplanted Kidneys 3
... painfree therapy stimulates the spincter and ... contractions and relaxation. By use of ... surgical operations (bladder liftings) may be ... can improve unsatisfying results. DETRUSAM intravesical ...
... operated dual-channel therapy system designed for use in ... Conti also includes a programme for treating pelvic ... Conti provokes a contraction of the pelvic floor, ... need exercising. In URGE incontinence, ELPHA 4 Conti ...
... templates for brachytherapy provide ... cost-effective solution. These templates ... faces to match existing ... Medical, Siemens, etc.) for ...
... HDR disposable template is designed ... and eliminate the need for ... with premium silicone molded over ... accurate needle placement while maintaining ...
Medicine Products: